不同潮气量机械通气对大鼠肺组织HMGB1表达的影响

目的观察不同潮气量机械通气大鼠肺组织高迁移率族蛋白1（HMGB1） mRNA及其蛋白的表达水平,探讨HMGB1在呼吸机相关性肺损伤（VILI）发病中的作用。方法24只雄性Wister大鼠随机分为对照组、小潮气量组和大潮气量组,分别采用原位分子杂交技术和免疫组织化学染色法检测肺组织HMGB1 mRNA及其蛋白的表达水平。结果与对照组和小潮气量组比较,大潮气量组大鼠肺组织HMGB1 mRNA及其蛋白表达水平明显升高（均P〈0.01）,小潮气量组与对照组各项指标比较差异无统计学意义（P〉0.05）。结论大潮气量机械通气可诱导肺组织HMGB1 mRNA及其蛋白高表达;HMGB1分泌增多导致肺组织炎症反应扩大,可能是呼吸机相关性肺损伤（VILI）发生的重要因素之一。     

白喉毒素突变体CRM197在大肠杆菌中表达纯化及性质研究

CRM197是一种白喉毒素突变体,作为载体蛋白广泛用于疫苗开发。将合成的CRM197基因片段克隆到表达载体pET25b中,转化大肠杆菌BL21(DE3),经IPTG诱导,CRM197获得高效表达,达到菌体总蛋白的20%。目的蛋白主要以包涵体形式存在,变性、复性后经DEAE阴离子交换、S-100分子筛纯化获得纯度高于95%的CRM197样品,用该蛋白样品免疫新西兰大白兔,免疫兔血清中检测到特异性抗体应答。急性毒性试验中,每只豚鼠皮下注射200μgCRM197纯化样品,未出现明显毒性反应症状,与之相比较,注射后48h内,20ng白喉毒素阳性对照组动物全部死亡。结果表明,利用本试验的表达策略,CRM197得到高效表达,并且具有良好的免疫原性和安全性,为其进一步生产及应用奠定基础。     

金葡菌α-溶血素致大鼠急性肺损伤时肺水通道蛋白AQP1表达的变化

目的观察金葡菌α-溶血素(α-Toxin)致急性肺损伤时大鼠肺部AQP1表达的变化。方法将24只健康雄性Wistar大鼠随机分为盐水对照组,α-Toxin 6h组,α-Toxin 10h组及α-Toxin 24h组,每组各6只。对照组给予腹腔内注入生理盐水;实验组则注入α-Toxin(5μg/100g),分别于6h、10h及24h采集标本。结果金葡菌α-Toxin可诱导大鼠急性肺损伤,肺组织出现不同程度的水肿、充血,动脉血氧下降,且损伤程度与毒素作用时间明显相关。免疫组化结果显示AQP1主要分布在肺微血管内皮,肺泡毛细血管内皮AQP1密度明显低于小血管内皮及细支气管旁毛细血管内皮(P0.05)。注入α-Toxin后6h肺AQP1表达显著下降,10h下降达高峰,24h后AQP1表达有部分恢复(P0.05)。结论α-Toxin可致大鼠肺损伤,并可同时下调肺AQP1表达,提示AQP1可能参与了金葡菌致急性肺损伤时肺内的异常液体转运。     

复方清下汤对脓毒症大鼠细胞因子白介素-1、白介素-6调控及肺损伤的作用

目的盲肠结扎穿孔导致大肠埃希菌腹膜炎进而建立脓毒症肺损伤大鼠模型,检测炎性反应时,细胞因子的调控变化,探讨肺水肿的形成机制。经复方清下汤处理后检测上述变化。方法将健康SD大鼠随机分为4组,每组10只:假手术组(SHAM组),只翻动盲肠,不做其他处理;脓毒血症肺损伤组(模型组),盲肠结扎穿孔诱发急性肺损伤(ALI)模型;盲肠结扎穿孔+复方清下汤组(造模后立即灌胃给药,造模后8 h再次灌胃1次,剂量:10 ml/kg);盲肠结扎穿孔+头孢哌酮舒巴坦组(抗生素舒普深)(造模后立即静脉注射1次,造模后8 h再次静脉注射1次,剂量:0.2 g/kg),造模24 h后收集标本。分别观察大鼠的一般状态,留取下腔静脉血清进行白介素-1(IL-1)、白介素-6(IL-6)的测定。镜下观察肺组织病理形态学改变,测量肺湿/干比值的变化。结果与SHAM组比较,模型组IL-1、IL-6水平明显升高(P0.01),肺间质和肺泡内水肿,伴大量红细胞渗出(出血)和纤维素沉积,肺泡间隔毛细血管内皮细胞高度肿胀。肺湿/干比值明显增加(P0.01),抗生素及中药处理组与模型组比较,IL-1、IL-6水平明显降低(P0.01),肺湿/干比值明显降低(P0.01),肺组织镜下表现:中药处理组及抗生素组组较模型组肺泡间隔变窄,毛细血管内皮细胞肿胀减轻,出血减轻,纤维素渗出明显减少。结论实验应用放免检测、显微镜观察以及称量肺湿/干比值等手段,进一步证实了脓毒血症大鼠肺损伤时血清中主要的炎性细胞因子IL-1、IL-6过度表达的情况,并从病理学角度,证实炎性介质的过度表达是造成脓毒症肺损伤的重要原因。经复方清下汤处理的动物模型得到相反结论,为治疗脓毒血症大鼠肺损伤提供一个可能的新的手段。     

西安市1995-2008年检出脊髓灰质炎疫苗病毒的急性弛缓性麻痹病例流行病学分析

分析脊髓灰质炎(脊灰)病毒(PV)的急性弛缓性麻痹(AFP)病例流行病学特征,提高对疫苗衍生脊灰病毒(VDPVs)和循环的疫苗衍生脊灰病毒(cVDPVs)的认识,增加AFP病例监测系统敏感性。对西安市1995-2008年检出的PV阳性AFP病例进行流行病学分析。对疫苗变异PV采用VP1基因核苷酸序列测定方法进行分子生物性状分析。西安市1995-2008年共检出PV13株,检出率4.29%。分离到的PV以II、III型为主,AFP病例散在发生,无聚集性。未全程免疫儿童(全程免疫儿童,年龄以≤1岁儿童为主(84.62%)。麻痹残留率高达84.62%。脊灰相关病例(VAPP)的发生危险性为0.24/100万。型内特征鉴定有1株为疫苗变异PV,经VP1基因核苷酸序列测定未达到VDPV的分类标准。维持无脊灰阶段,存在着VDPV和发生cVDPVs的可能,在保持高水平脊髓灰质炎疫苗(OPV)免疫覆盖率的同时,高质量的AFP病例流行病学监测和病毒学监测工作,具有重要的现实意义。     

Role of post-translational modifications of HTLV-1 Tax in NF-κB activation

Human T-cell leukemia virus type 1 (HTLV-1), the first human retrovirus discovered, is the etiological agent of adult-T-cell leukemia/lymphoma. The HTLV-1 encoded Tax protein is a potent oncoprotein that deregulates gene expression by constitutively activating nuclear factor-κB (NF-κB). Tax activation of NF-κB is critical for the immortalization and survival of HTLV-1-infected T cells. In this review, we summarize the present knowledge on mechanisms underlying Tax-mediated NF-κB activation, with an emphasis on post-translational modifications of Tax.     

Brain distribution of carboxy terminus of Hsc70-interacting protein (CHIP) and its nuclear translocation in cultured cortical neurons following heat stress or oxygen–glucose deprivation

Carboxy terminus of Hsc70-interacting protein (CHIP) is thought to be a cytoprotective protein with protein quality control roles in neurodegenerative diseases and myocardial ischemia. This study describes the localization of CHIP expression in normal rodent brain and the early CHIP response in primary cultures of cortical neurons following ischemic stress models: heat stress (HS) and oxygen–glucose deprivation (OGD). CHIP was highly expressed throughout the brain, predominantly in neurons. The staining pattern was primarily cytoplasmic, although small amounts were seen in the nucleus. More intense nuclear staining was observed in primary cultured neurons which increased with stress. Nuclear accumulation of CHIP occurred within 5–10 min of HS and decreased to baseline levels or lower by 30–60 min. Decrease in nuclear CHIP at 30–60 min of HS was associated with a sharp increase in delayed cell death. While no changes in cytoplasmic CHIP were observed immediately following OGD, nuclear levels of CHIP increased slightly in response to OGD durations of 30 to 240 min. OGD-induced increases in nuclear CHIP decreased slowly during post-ischemic recovery. Nuclear CHIP decreased earlier in recovery following 120 min of OGD (4 h) than 30 min of OGD (12 h). Significant cell death first appeared between 12 and 24 h after OGD, again suggesting that delayed cell death follows closely behind the disappearance of nuclear CHIP. The ability of CHIP to translocate to and accumulate in the nucleus may be a limiting variable that determines how effectively cells respond to external stressors to facilitate cell survival. Using primary neuronal cell cultures, we were able to demonstrate rapid translocation of CHIP to the nucleus within minutes of heat stress and oxygen–glucose deprivation. An inverse relationship between nuclear CHIP and delayed cell death at 24 h suggests that the decrease in nuclear CHIP following extreme stress is linked to delayed cell death. Our findings of acute changes in subcellular localization of CHIP in response to cellular stress suggest that cellular changes that occur shortly after exposure to stress ultimately impact on the capacity and capability of a cell to recover and survive.     

Long-term comparison of balloon angioplasty with provisional stenting versus routine stenting in patients with non-ST-elevation acute coronary syndrome

Background. In patients with unstable angina or non-ST-elevation acute coronary syndrome (NSTE-ACS) who are eligible for PCI, routine stenting is the recommended treatment strategy, based on the opinion of experts. Provisional stenting may provide a viable alternative by retaining the early benefits of stenting without its potential late hazards. Method. Patients with NSTE-ACS were randomised to provisional or routine stenting after coronary angiography. Patients were followed for up to ten years. The occurrence of major adverse cardiac events (MACE) was recorded. Results. 237 consecutive patients with NSTE-ACS were randomly assigned to routine stenting (n=116) or provisional stenting (n=121). No difference in the incidence of MACE at 30 days was observed. At six months, angiographic restenosis was lower in the routine stenting group (41 vs. 20%, p=0.02), paralleled by more MACE in the provisional stenting group at one year (40.5 vs. 27.6%, p=0.036). At complete follow-up the difference in MACE was not significant (61.2 vs. 50%, p=0.084) because of relatively more target lesion revascularisations in the routine stent group. There was no difference in the incidence of very late stent thrombosis (1.7 vs. 3.4%, p=0.439). The only independent predictor of MACE was β-blocker use (RR 0.62 [0.431; 0.892] p=0.010). Conclusion. In selective patients with NSTE-ACS, routine stenting was more beneficial than provisional stenting for a period of up to five years, driven by a reduction in repeat revascularisation procedures. After this period, the benefit was no longer significant. Beta-blocker use was the only independent predictor of MACE throughout the complete follow-up period. (Neth Heart J 2010;18:307-313.)     

Expression proteomics of acute promyelocytic leukaemia cells treated with methotrexate

Methotrexate was first introduced as a cytotoxic agent that inhibits nucleotide biosynthesis in various cancer disorders; its molecular mechanism remains elusive. To understand the molecular mechanism by which methotrexate induces apoptosis, we analyzed the resulting intracellular protein changes in methotrexate-treated acute promyelocytic leukaemia (HL-60) cells by cysteine-labeled differential in-gel electrophoresis (CL-DIGE) combined with mass spectrometry. Initial CL-DIGE analysis revealed that 24 proteins were differentially expressed (p < 0.05) in the HL-60 cell proteome after treatment with 2.5 µM methotrexate for 72 h. We found that three structural α4, α5, α7 proteasome subunits, a non-catalytic β3 and two 26S regulatory proteasome subunits were down-regulated in methotrexate-treated HL-60 cells. Western blot analyses further showed that the inhibition of proteasome subunits is accompanied by suppression of NF-κB subunits and promotes the accumulation of ubiquitinated proteins. Furthermore, methotrexate activated unfolded protein response by inducing the expression of endoplasmic reticulum-resident proteins such as calreticulin, protein disulphide isomerase A3 and A4, and 78 kDa glucose regulated protein in a time-dependent manner. Altogether, our findings demonstrated that targeting NF-κB, structural and regulatory proteasome subunits with methotrexate may provide new insight into understanding methotrexate-induced apoptotic activities in HL-60 cells.     

Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: A comparative proteomic approach

Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease. A major concern in imatinib treatment is the emergence of resistance to the drug. Here we used the imatinib-resistant KCL22R and imatinib-sensitive KCL22S cells in which none of the known resistance mechanisms has been detected and hence novel Bcr-Abl activity-independent mechanisms could be envisaged. We characterized proteins that were differentially expressed between the KCL22R and KCL22S cells. Using two-dimensional differential gel electrophoresis coupled with mass spectrometry and Western blot analysis we identified 51 differentially expressed proteins: 27 were over-expressed and 24 were under-expressed in KCL22R versus KCL22S cells. Several of these proteins are likely to be involved in such survival mechanisms as modulation of redox balance and activation of anti-apoptotic pathways mediated by NF-κB and Ras-MAPK signaling. The data reported may be useful for further studies on mechanisms of imatinib resistance and for the screening of biomarkers to develop new combinatorial therapeutic approaches.